CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

BACKGROUND: The Hu5F9-G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab to eliminate B-cell non-Hodgkin’s lymphoma cells by enhancing macrophage-mediated antibody-dependent cellular phagocytosis....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Advani, Ranjana, Flinn, Ian, Popplewell, Leslie, Forero, Andres, Bartlett, Nancy L., Ghosh, Nilanjan, Kline, Justin, Roschewski, Mark, LaCasce, Ann, Collins, Graham P., Tran, Thu, Lynn, Judith, Chen, James Y., Volkmer, Jens-Peter, Agoram, Balaji, Huang, Jie, Majeti, Ravindra, Weissman, Irving L., Takimoto, Chris H., Chao, Mark P., Smith, Sonali M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058634/
https://ncbi.nlm.nih.gov/pubmed/30380386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1807315
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados